Clinical Trials Logo

Muscular Dystrophy, Duchenne clinical trials

View clinical trials related to Muscular Dystrophy, Duchenne.

Filter by:

NCT ID: NCT03218995 Completed - Clinical trials for Duchenne Muscular Dystrophy

Study of Eteplirsen in Young Participants With Duchenne Muscular Dystrophy (DMD) Amenable to Exon 51 Skipping

Start date: August 16, 2017
Phase: Phase 2
Study type: Interventional

This is a multicenter, open-label, dose-escalation study to evaluate the safety, tolerability, and PK of once-weekly IV infusions of eteplirsen in approximately 12 male participants, ages 6 months to 48 months (inclusive), who have genotypically confirmed DMD with a deletion mutation amenable to exon 51 skipping.

NCT ID: NCT03179631 Completed - Clinical trials for Nervous System Diseases

Long-Term Outcomes of Ataluren in Duchenne Muscular Dystrophy

Start date: July 6, 2017
Phase: Phase 3
Study type: Interventional

This study is a long-term study of ataluren in participants with nonsense mutation Duchenne muscular dystrophy.

NCT ID: NCT03167255 Completed - Clinical trials for Duchenne Muscular Dystrophy

Extension Study of NS-065/NCNP-01 in Boys With Duchenne Muscular Dystrophy (DMD)

Start date: July 6, 2017
Phase: Phase 2
Study type: Interventional

This is an open-label, extension study of NS-065/NCNP-01 administered intravenously once weekly for an additional 192 weeks to boys with DMD who complete Study NS-065/NCNP-01-201.

NCT ID: NCT03127241 Completed - Clinical trials for Muscular Dystrophies

User-centred Assistive System for Arm Functions in Neuromuscular Subjects

USEFUL
Start date: June 16, 2017
Phase: N/A
Study type: Interventional

Restore a lost function is a special experience for people affected by neuromuscular evolutive diseases. "From the patient's point of view improvement is measured by regaining lost abilities,-by being able to do something -anything-today I couldn't do yesterday ". Upper limb pain, stiffness and activity limitations have a crucial role in reducing patients' autonomy and worsening quality of life. Real users' needs have been identified thought several workshops, and even if the commercial products might assure a benefit to some users and meet most of their requirements, so far a validation of the use of such devices by people with neuromuscular disease is missing. We aim at field-testing the improvement in arm functions provided by the use of some commercial devices and assessing their impact to users' quality of life and independence. This step is essential to assure a widespread accessibility to these devices for most of the potential users, possibly providing health providers with direction and guidance towards Health Technology Assessment. Clinical Trial design - The study proposes on-field validation of JAECO WREX, passive antigravity exoskeleton; and Armon Ayura, motorized arm exoskeleton for gravity compensation in a randomized controlled trial with crossover design. The clinical study will is multi-centric, involving both MEDEA and VALDUCE, and received the Ethical Committee approval.

NCT ID: NCT03076814 Withdrawn - Clinical trials for Becker Muscular Dystrophy

Functional Muscle Ischemia With Tadalafil Treatment in Becker Muscular Dystrophy

Start date: March 2012
Phase: N/A
Study type: Interventional

the Investigator will test the hypothesis that short term PDE5A inhibition (with tadalafil) will reduce post-exercise edema by MRI in males with Becker Muscular Dystrophy.

NCT ID: NCT03067831 Recruiting - Clinical trials for Duchenne Muscular Dystrophy

Bone Marrow-Derived Autologous Stem Cells for the Treatment of Duchenne Muscular Dystrophy

Start date: September 2015
Phase: Phase 1/Phase 2
Study type: Interventional

This study is single arm, single center trial to study the safety and efficacy of bone marrow-derived autologous specific populations of stem cells and mesenchymal stem cells for the treatment of Duchenne Muscular Dystrophy (DMD).

NCT ID: NCT03057002 Recruiting - Clinical trials for Duchenne Muscular Dystrophy

UTSW HP [13-C] Pyruvate Injection in HCM

HPHCM
Start date: May 1, 2018
Phase:
Study type: Observational

The study objective is to identify the earliest changes in energy substrate metabolism in patients with cardiomyopathies (CMP). To achieve this objective, we plan first to test the hypothesis that patients with CMP present focal alterations in myocardial hyperpolarized [1-13C]pyruvate flux.

NCT ID: NCT03039686 Completed - Clinical trials for Duchenne Muscular Dystrophy

Clinical Trial to Evaluate the Efficacy, Safety, and Tolerability of RO7239361 in Ambulatory Boys With Duchenne Muscular Dystrophy

Start date: July 6, 2017
Phase: Phase 2/Phase 3
Study type: Interventional

This is a multi-center, randomized, double-blind, placebo-controlled study to assess the efficacy, safety and tolerability of two different weekly doses of RO7239361 in ambulatory boys with Duchenne Muscular Dystrophy (DMD).

NCT ID: NCT03038399 Completed - Clinical trials for Duchenne Muscular Dystrophy

Long-term Extension Study to Assess Vamorolone in Boys With Duchenne Muscular Dystrophy (DMD)

Start date: February 2, 2017
Phase: Phase 2
Study type: Interventional

This long-term extension study is an open-label, multiple-dose study to evaluate the long-term safety, tolerability, efficacy and PD of vamorolone administered once daily by liquid oral suspension over a Treatment Period of 24 months to young boys with DMD who participated in the VBP15-002 Phase IIa and VBP15-003 Phase IIa extension core studies.

NCT ID: NCT03002298 Completed - Clinical trials for Duchenne Muscular Dystrophy

Virtual Reality in Individuals With Duchenne Muscular Dystrophy

Start date: January 2016
Phase: N/A
Study type: Interventional

With the growing accessibility of computer-assisted technology, one option for rehabilitation programs for individuals with Duchenne muscular dystrophy (DMD) is the use of virtual reality environments to enhance motor practice. Thus, it is important to examine whether performance improvements in the virtual environment generalize to the natural environment. To examine this issue, we had 64 individuals, 32 of which were individuals with DMD and 32 were typically developing individuals. The groups practiced two coincidence timing tasks. In the more tangible button-press task, the individuals were required to 'intercept' a falling virtual object at the moment it reached the interception point by pressing a key on the computer. In the more abstract task, they were instructed to 'intercept' the virtual object by making a hand movement in a virtual environment using a webcam.